OTSUKA AMERICA PHARMACEUTICAL, INC.

Lobbying for OTSUKA AMERICA PHARMACEUTICAL, INC.

Filing 1st Quarter - Report

Reporting period

1st Quarter 2026

Jan 1 - Mar 31 · Posted Apr 17, 2026

Expenses

$210,000.00

What this organization spent lobbying with its own staff. Reported using A: the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

Maryland

Official filing document

Government bodies contacted 2

HOUSE OF REPRESENTATIVES
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 1

HR 1518
New Era of Preventing End-Stage Kidney Disease Act

Lobbying activity 5

Medicare/Medicaid

Implementation of the Inflation Reduction Act. Issues related to Medicare Part D redesign's impact on low-income subsidy beneficiaries.

Health Issues

Issues relating to early detection of PTSD, mental health parity and coordinated care and mental health equity. PBM reform. Issues related to rare nephrology/kidney diseases, 340B reform, psychedelics treatments for PTSD and mental health. H.R. 1518, the New Era of Preventing End-Stage Kidney Disease Act. Issues related to drug pricing, foreign reference pricing, biomedical research, and pharmaceutical supply chain.

Budget/Appropriations

Appropriations for the Department of Health & Human Services, the Department of Veterans Affairs, and the Department of Defense.

Veterans

Health care policies relating to mental health and PTSD, including authorizations and appropriations for the Department of Veterans Affairs related to mental health and PTSD.

Tariff (miscellaneous tariff bills)

Issues related to tariffs on pharmaceuticals and pharmaceutical supply chain.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.